Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?

Bone

Volumn 62, Issue , 2014, Pages 56-63

  Mutsaers, Anthony J ^a   Walkley, Carl R ^b,c  

^a UNIVERSITY OF GUELPH   (Canada)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Mesenchymal stem cell; Osteoblast; Osteosarcoma; P53; Tumor initiating cell

Indexed keywords

BIOINFORMATICS; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL FATE; CELL HETEROGENEITY; CELL POPULATION; CELL TYPE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR INITIATING CELL; ANIMAL; BIOLOGY; CANCER STEM CELL; CELL LINEAGE; MESENCHYMAL STROMA CELL; PATHOLOGY;

ANIMALS; CELL LINEAGE; COMPUTATIONAL BIOLOGY; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASTIC STEM CELLS; OSTEOBLASTS; OSTEOSARCOMA;

EID: 84896696942     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.02.003     Document Type: Review

References (81)

1. Nombela-Arrieta C., Ritz J., Silberstein L.E. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 2011, 12:126-131.
2. Whelan J., McTiernan A., Cooper N., Wong Y.K., Francis M., Vernon S., et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 2012, 131:E508-E517.
3. Damron T.A., Ward W.G., Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin Orthop Relat Res 2007, 459:40-47.
4. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
5. Xiao W., Mohseny A.B., Hogendoorn P.C., Cleton-Jansen A.M. Mesenchymal stem cell transformation and sarcoma genesis. Clin Sarcoma Res 2013, 3:10.
6. Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C., et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005, 65:11459-11468.
7. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11:421-429.
8. Castillero-Trejo Y., Eliazer S., Xiang L., Richardson J.A., Ilaria R.L. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res 2005, 65:8698-8705.
9. Riggi N., Suva M.L., Suva D., Cironi L., Provero P., Tercier S., et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008, 68:2176-2185.
10. Miyagawa Y., Okita H., Nakaijima H., Horiuchi Y., Sato B., Taguchi T., et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008, 28:2125-2137.
11. Sorensen P.H., Lessnick S.L., Lopez-Terrada D., Liu X.F., Triche T.J., Denny C.T. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994, 6:146-151.
12. Chromosomal translocations in Ewing's sarcoma. N Engl J Med 1983, 309:496-498.
13. Turc-Carel C., Aurias A., Mugneret F., Lizard S., Sidaner I., Volk C., et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988, 32:229-238.
14. Tarpey P.S., Behjati S., Cooke S.L., Van Loo P., Wedge D.C., Pillay N., et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 2013, 45:923-926.
15. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011, 224:334-343.
16. Mirabello L., Troisi R.J., Savage S.A. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009, 125:229-234.
17. Ragland B.D., Bell W.C., Lopez R.R., Siegal G.P. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 2002, 82:365-373.
18. Bacci G., Longhi A., Fagioli F., Briccoli A., Versari M., Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27year experience at Rizzoli Institute, Italy. Eur J Cancer 2005, 41:2836-2845.
19. Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010, 11:670-678.
20. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009, 115:1531-1543.
21. Weiss A., Khoury J.D., Hoffer F.A., Wu J., Billups C.A., Heck R.K., et al. Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Cancer 2007, 109:1627-1637.
22. Birch J.M., Blair V., Kelsey A.M., Evans D.G., Harris M., Tricker K.J., et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998, 17:1061-1068.
23. Garber J.E., Goldstein A.M., Kantor A.F., Dreyfus M.G., Fraumeni J.F., Li F.P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991, 51:6094-6097.
24. Wong F.L., Boice J.D., Abramson D.H., Tarone R.E., Kleinerman R.A., Stovall M., et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997, 278:1262-1267.
25. Hansen M.F., Koufos A., Gallie B.L., Phillips R.A., Fodstad O., Brogger A., et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 1985, 82:6216-6220.
26. Wadayama B., Toguchida J., Shimizu T., Ishizaki K., Sasaki M.S., Kotoura Y., et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994, 54:3042-3048.
27. Wang L.L., Gannavarapu A., Kozinetz C.A., Levy M.L., Lewis R.A., Chintagumpala M.M., et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003, 95:669-674.
28. Wang L.L., Levy M.L., Lewis R.A., Chintagumpala M.M., Lev D., Rogers M., et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001, 102:11-17.
29. Dela Cruz F.S. Cancer stem cells in pediatric sarcomas. Front Oncol 2013, 3:168.
30. Aubin J.E. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001, 2:81-94.
31. Rodda S.J., McMahon A.P. Distinct roles for hedgehog and canonical wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
32. Franz-Odendaal T.A., Hall B.K., Witten P.E. Buried alive: how osteoblasts become osteocytes. Dev Dyn 2006, 235:176-190.
33. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
34. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008, 22:1662-1676.
35. Kuijjer M.L., Hogendoorn P.C., Cleton-Jansen A.M. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer 2013, 133:2512-2521.
36. Kuijjer M.L., Rydbeck H., Kresse S.H., Buddingh E.P., Lid A.B., Roelofs H., et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012, 51:696-706.
37. Di Fiore R., Fanale D., Drago-Ferrante R., Chiaradonna F., Giuliano M., De Blasio A., et al. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness. J Cell Physiol 2013, 228:1189-1201.
38. Gibbs C.P., Levings P.P., Ghivizzani S.C. Evidence for the osteosarcoma stem cell. Curr Pract Orthop 2011, 22:322-326.
39. Martins-Neves S.R., Lopes A.O., do Carmo A., Paiva A.A., Simoes P.C., Abrunhosa A.J., et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 2012, 12:139. [2407-12-139].
40. Trucco M., Loeb D. Sarcoma stem cells: do we know what we are looking for?. Sarcoma 2012, 2012:291705.
41. Mohseny A.B., Szuhai K., Romeo S., Buddingh E.P., Briaire-de Bruijn I., de Jong D., et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009, 219:294-305.
42. Rubio R., Garcia-Castro J., Gutierrez-Aranda I., Paramio J., Santos M., Catalina P., et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010, 70:4185-4194.
43. Rodriguez R., Rubio R., Masip M., Catalina P., Nieto A., de la Cueva T., et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 2009, 11:397-407.
44. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
45. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
46. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
47. Quintana E., Piskounova E., Shackleton M., Weinberg D., Eskiocak U., Fullen D.R., et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med 2012, 4. [159ra149].
48. Ng A.J., Mutsaers A.J., Baker E.K., Walkley C.R. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012, 2:19. [3329-2-19].
49. Post S.M. Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res 2012, 2:20. [3329-2-20].
50. Janeway K.A., Walkley C.R. Modeling human osteosarcoma in the mouse: from bedside to bench. Bone 2010, 47:859-865.
51. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
52. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
53. Lin P.P., Pandey M.K., Jin F., Raymond A.K., Akiyama H., Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009, 30:1789-1795.
54. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 2008, 105:11851-11856.
55. Mutsaers A.J., Ng A.J., Baker E.K., Russell M.R., Chalk A.M., Wall M., et al. Modeling distinct osteosarcoma subtypes in vivo using cre:Lox and lineage-restricted transgenic shRNA. Bone 2013, 55:166-178.
56. Haldar M., Hancock J.D., Coffin C.M., Lessnick S.L., Capecchi M.R. A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 2007, 11:375-388.
57. Haldar M., Hedberg M.L., Hockin M.F., Capecchi M.R. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 2009, 69:3657-3664.
58. Haldar M., Randall R.L., Capecchi M.R. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008, 466:2156-2167.
59. David E., Blanchard F., Heymann M.F., De Pinieux G., Gouin F., Redini F., et al. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011, 2011:932451.
60. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646.
61. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
62. Gronthos S., Zannettino A.C., Hay S.J., Shi S., Graves S.E., Kortesidis A., et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835.
63. Soleimani M., Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 2009, 4:102-106.
64. Chan C.K., Chen C.C., Luppen C.A., Kim J.B., DeBoer A.T., Wei K., et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 2009, 457:490-494.
65. Chan C.K., Lindau P., Jiang W., Chen J.Y., Zhang L.F., Chen C.C., et al. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proc Natl Acad Sci U S A 2013, 110:12643-12648.
66. Wagner W., Wein F., Seckinger A., Frankhauser M., Wirkner U., Krause U., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
67. Rubio R., Gutierrez-Aranda I., Saez-Castillo A.I., Labarga A., Rosu-Myles M., Gonzalez-Garcia S., et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene 2013, 32:4970-4980.
68. Semerad C.L., Christopher M.J., Liu F., Short B., Simmons P.J., Winkler I., et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
69. Shimizu T., Ishikawa T., Sugihara E., Kuninaka S., Miyamoto T., Mabuchi Y., et al. C-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010, 29:5687-5699.
70. Calo E., Quintero-Estades J.A., Danielian P.S., Nedelcu S., Berman S.D., Lees J.A. Rb regulates fate choice and lineage commitment in vivo. Nature 2010, 466:1110-1114.
71. Molyneux S.D., Di Grappa M.A., Beristain A.G., McKee T.D., Wai D.H., Paderova J., et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 2010, 120:3310-3325.
72. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
73. Huntly B.J., Shigematsu H., Deguchi K., Lee B.H., Mizuno S., Duclos N., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6:587-596.
74. Huntly B.J., Gilliland D.G. Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell 2004, 6:199-201.
75. Xiong J., O'Brien C.A. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 2012, 27:499-505.
76. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009, 119:837-851.
77. Kuijjer M.L., Peterse E.F., van den Akker B.E., Briaire-de Bruijn I.H., Serra M., Meza-Zepeda L.A., et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013, 13:245. [2407-13-245].
78. Kelly A.D., Haibe-Kains B., Janeway K.A., Hill K.E., Howe E., Goldsmith J., et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med 2013, 5:2.
79. Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.M., et al. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One 2012, 7:e48262.
80. Swinney D.C., Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519.
81. Chen X., Stewart E., Shelat A.A., Qu C., Bahrami A., Hatley M., et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013, 24:710-724.